Key result
GDF-15 proposed as key molecular link driving cardiometabolic decline in obstructive sleep apnea.
This hypothesis-generating review proposes Growth Differentiation Factor-15 (GDF-15) as a candidate molecular bridge linking chronic intermittent hypoxia and carotid body hyperactivity to systemic cardiovascular decline in obstructive sleep apnea.
Answers are grounded in this paper and cite their sources.
No immediate clinical role for GDF-15 in OSA; hypothesis-generating for mechanistic trials linking hypoxia to cardiometabolic risk.
Obstructive sleep apnea (OSA) is a worldwide epidemic and is strongly associated with cardiometabolic comorbidities such as hypertension, arrhythmias and heart failure. Its principal cardiovascular pathological driver is chronic intermittent hypoxia (CIH). CIH induces maladaptive plasticity in the carotid body (CB), the main peripheral oxygen sensor. Profound nitro-oxidative stress and localized inflammation lead to relentless sympathetic overactivity and autonomic imbalance, causing persistent CB hyperactivity. Although this chemoreflex arc is well-characterized, the molecular messengers linking local hypoxemic stress to systemic cardiovascular decline are poorly defined. We propose that Growth Differentiation Factor-15 (GDF-15) is a very likely candidate for this bridge. GDF-15 is a well-established cardiovascular prognostic biomarker. It is strongly upregulated by hypoxia, oxidative stress and HIF stabilization. Plasma GDF-15 is related to the severity of OSA, nocturnal hypoxemia and arrhythmogenic remodeling, and is progressively reduced in clinical settings after continuous positive airway pressure (CPAP) therapy. In addition to being a systemic biomarker, we speculate that local production of GDF-15 in the oxidative CB microenvironment may have autocrine / paracrine effects that maintain glomus cell hyperexcitability but this remains to be proven experimentally. Also, circulating GDF-15 may act on brainstem GFRAL receptors to enhance chemoreflex drive. We emphasize that this peripheral to central axis, localized CB signaling is a theoretical model that should be tested directly in the lab. Ultimately, therapeutic targeting of this GDF-15 axis at the CB-brainstem interface may provide a life-changing strategy to ameliorate complications of sleep-disordered breathing.
No takes yet. Share an insight, caveat, or question.
Chowdhury et al. (2026) conducted a review in Obstructive sleep apnea (OSA) and associated cardiometabolic comorbidities (hypertension, arrhythmias, heart failure). Growth Differentiation Factor-15 (GDF-15) signaling at the carotid body-brainstem interface was evaluated. Growth Differentiation Factor-15 (GDF-15) is proposed as a theoretical molecular link between intermittent hypoxia, carotid body hyperactivity, and cardiometabolic decline in obstructive sleep apnea.
Synapse has enriched 10 related papers. Consider them for comparative context: